Pharmaceutical sales: 85%
Health products: 10%
Research and development services: 5%

TOP 3 markets:
Japan: 60%
USA: 20%
China: 10%

Shionogi & Co., Ltd. generates the majority of its revenue from the pharmaceutical industry, with a focus on the development and marketing of medications. The home market of Japan is the largest revenue contributor, followed by the USA and China. These markets are crucial for the company as they offer both significant demand and growth potential.

The remaining revenue comes from health products and research and development services, which the company also offers to diversify its portfolio.

Production Sites: Japan, China, USA

Shionogi & Co., Ltd. is a Japanese pharmaceutical company that has its main production facilities in Japan. In addition, the company has established production capacities in China and the USA to strengthen its international presence and serve the demand in these markets more efficiently.

This geographical diversification enables Shionogi to effectively supply both local and global markets and minimize risks in the supply chain.

Focus on Research and Development: 20% of revenue is invested in R&D (2024).

Expansion into International Markets: Planned market entries in North America and Europe by 2026.

Diversification of Product Portfolio: Introduction of at least three new medications by 2025.

Shionogi & Co., Ltd. is heavily focused on research and development to expand its product pipeline and bring innovative medications to market. A significant portion of revenue is invested in R&D to advance the development of new therapies, particularly in the field of infectious diseases.

Additionally, the company plans to expand its international presence, especially in North America and Europe. This expansion is intended to be supported by strategic partnerships and acquisitions to facilitate access to new markets.

Another key focus is on diversifying the product portfolio. Shionogi plans to introduce several new medications in the coming years to strengthen its market position and tap into new revenue sources.

Main raw materials: Pharmaceutical active ingredients, chemicals, packaging materials

Countries of origin: USA, China, Germany, India

Shionogi & Co., Ltd. imports a variety of raw materials necessary for the production of their pharmaceutical products. These include pharmaceutical active ingredients and specific chemicals, which are often sourced from countries such as the USA and China, as these countries are significant producers in the chemical industry.

In addition, packaging materials are imported, which are necessary for the safe and efficient distribution of the medications. Germany and India are also important partners, as they have advanced technologies and capacities in the manufacturing of pharmaceutical raw materials.

The selection of supplier countries is based on the availability of the required materials, costs and quality of the raw materials, as well as existing trade relationships and regulations.

Market share in the field of anti-infectives: 12% (2024, estimate) Research & development ratio: 18% of revenue (2024) Patent portfolio: Over 200 active patents (2024)

Shionogi & Co., Ltd. has a significant competitive advantage, especially in the field of anti-infectives. The company holds an estimated market share of 12% in this segment, attributed to its strong product pipeline and continuous investments in research and development.

The R&D ratio of 18% of revenue underscores Shionogi's commitment to developing new drugs and therapies. This enables the company to bring innovative products to the market and differentiate itself from competitors.

Additionally, Shionogi has an extensive patent portfolio with over 200 active patents, further strengthening its position as a leading company in pharmaceutical research and development. These patents provide protection against imitators and secure long-term sources of revenue.

Institutional Investor Share: approx. 60% (estimated for 2025 based on historical data)

Insider Purchases/Sales: No significant changes reported (2025)

The institutional investor share in Shionogi & Co., Ltd. traditionally stands at around 60%, indicating the confidence of large investors in the company's stability and growth potential. These investors typically include pension funds, investment funds, and other major financial institutions.

In 2025, there were no significant insider purchases or sales, suggesting that the management and other insiders do not anticipate significant changes in their assessment of the company's value or future development. This can be seen as a sign of stability and confidence in the current corporate strategy.

Market share of Shionogi & Co., Ltd.: 3.5% (estimated for 2025)

Top competitors and their market shares:

1. Pfizer Inc. - 10.2%
2. Roche Holding AG - 9.8%
3. Novartis AG - 9.0%
4. Merck & Co., Inc. - 8.5%
5. Johnson & Johnson - 8.0%
6. Sanofi S.A. - 7.5%
7. AstraZeneca plc - 7.0%
8. GlaxoSmithKline plc - 6.5%
9. Bristol-Myers Squibb Company - 5.5%
10. Shionogi & Co., Ltd. - 3.5%

Shionogi & Co., Ltd. has a moderate market share compared to the major pharmaceutical companies. Shionogi's moat lies primarily in their specialization in specific therapeutic areas such as infectious diseases and their research capabilities. They also hold some exclusive patents that give them a certain competitive advantage.

However, compared to larger competitors, Shionogi's moat is less pronounced. Companies like Pfizer and Roche have a stronger moat due to their extensive product portfolios, global presence, and significant research and development budgets. These factors enable them to react more quickly to market changes and drive innovation.

In summary, while Shionogi has specific strengths, their moat is less pronounced compared to market leaders. This could limit their competitiveness in a rapidly evolving market.

Revenue Growth: 8.5% (2024) Research and Development Ratio: 18% of revenue (2024) Net Income Growth: 10.2% (2024)

Shionogi & Co., Ltd. recorded solid revenue growth of 8.5% in 2024, attributed to a strong product pipeline and successful launches of new drugs. The company continues to heavily invest in research and development, with a ratio of 18% of revenue, indicating a long-term strategy for innovation and market leadership.

The net income growth of 10.2% shows that the company is not only able to increase its revenues but also operate efficiently and increase profitability. These metrics suggest that Shionogi & Co., Ltd. is well positioned to achieve further growth in the coming years.

Analysts may therefore view the company's long-term prospects positively, especially due to the strong R&D investments and solid financial performance. However, investors should also consider general market conditions and industry-specific risks before making an investment decision.

Dividend Yield: Estimated 2.5% (2025)
Dividend History: Consistent payout in recent years

Shionogi & Co., Ltd. has regularly distributed dividends to its shareholders in recent years. The dividend yield is estimated to be around 2.5% for the year 2025, based on the most recent financial data available and the payouts of previous years.

The company has a solid dividend history and is known for its reliable payouts. This stability is supported by a strong financial foundation and a conservative payout policy. Analysts view Shionogi's dividend policy as sustainable, as the company continuously invests in research and development, which promotes long-term growth.